-
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group
Источник: Buzz FX / 01 мар 2025 07:51:14 America/New_York
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group Written by MarketBeat March 1, 2025 Share Link copied to clipboard. Research analysts at The Goldman Sachs Group assumed coverage on shares of Summi
Read more...